Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its TNX-801 vaccine candidate at the 2025 Vaccine Congress in Vienna.
The biopharma company highlighted that its recombinant horsepox-based vaccine demonstrates promising potential to provide long-lasting immunity while being significantly more attenuated than earlier orthopoxvirus vaccines. Notably, the data showed that subcutaneous delivery of TNX-801 offers protection comparable to percutaneous administration, which the company intends to focus on for further development.
Preclinical results indicated that TNX-801 replicates 27 to 119 times less in primary human dermal cells than currently licensed vaccinia vaccines. In interferon receptor knockout mice, the vaccine exhibited up to a 100,000-fold reduction in virulence compared to traditional vaccines.
Additionally, a single dose of TNX-801 elicited robust binding and neutralizing antibody responses in various animal models, including immunocompromised subjects. Vaccinated macaques survived lethal exposure to Clade I mpox without developing lesions, and rabbits remained fully protected for over a year.
The vaccine candidate is being developed to help control mpox outbreaks and prepare for potential smallpox threats, with both the WHO and CDC maintaining mpox as a significant public health issue.
Tonix believes that TNX-801’s single-dose regimen could simplify outbreak management by removing the need for multiple immunizations required by existing vaccines.
Tonix Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.